TP53 and hepatocellular carcinoma: Shen et al. [49] divided 895 HCC patients into three cohorts and demonstrated that the TP53 R249S mutation in ctDNA, detected with droplet digital polymerase chain reaction (PCR), represents a promising prognostic biomarker for HCC patients, regardless of whether they have undergone LR.